Pharmsource Strategic Advantage

Market Intelligence

Contract Service Providers

Emerging Markets Manufacturers

Products by Manufacturer

Strategic Searches

> Search by Mergers and Acquisitions

> Search by Ownership Type

Subject Search

Market Intelligence - News & Analysis

Bio/Pharmaceutical Outsourcing Report

	Current Monthly Report
	Archive

Emerging Markets Outsourcing Report

	Current Quarterly Report
	Archive

Trend Reports and Analyses

What’s Next for the CDMO Business?

Jim Miller's presentation at Contract Pharma 2017 in New Brunswick, NJ. Login

Contract Dose Manufacturing Industry by the Numbers: Composition, Size, Market Share and Outlook – 2017 Edition

Growth of the CMO industry is expected to continue to slow relative to overall industry growth. This is primarily a consequence of a decline in unit volume per product, while outsourcing propensity has remained stable for a decade. Login \| Learn more...

M&A in the CMC Services Industry: Implications and Outlook

M&A is reshaping the bio/pharmaceutical contract development services industry. Established CMOs and CROs are pursuing acquisitions to drive scale and broaden their offerings, while private equity are anxious to either gain a presence in the industry or cash in on investments already made. Login \| Learn more...

CMO Scorecard: Outsourcing of NDA Approvals and CMO Performance – 2017 Edition

This report analyzes the performance of the drug product CMO industry using NDA approvals as the primary indicator of performance. CMO Scorecard is critical for benchmarking the performance of the CMO industry and the relative performance of major CMOs. Login \| Learn more...

Follow the Money: The Outlook for Outsourced Spending on Early Development Services

Demand for development services to support Phase 1 and Phase 2 clinical trials is driving double-digit growth for CROs and CDMOs. Demand for clinical manufacturing services is actually outstripping industry capacity and leading to delays in getting clinical trial materials needed for studies. This report exams the link between external funding sources and early drug development, and addresses the outlook for continued funding over the next two years. Login \| Learn more...

Bio/Pharma CapEx Trends 2016

This Trend Report analyzes recent trends in capital spending by bio/pharmaceutical companies and assesses the implications for the CMO industry. It tracks spending by major segments of the bio/pharma industry, with detailed information on investments by global and generic biopharma companies. Login \| Learn more...

Contract Manufacturing Market Opportunities for Antibody Drug Conjugates

This expert trend report is an indispensable resource for understanding the technical developments in the Antibody Drug Conjugate (ADC) sector and the scale of the commercial opportunities and risks for CMOs. The CDMO sector is investing significant resources to expand its capabilities in the ADC arena. More than 20 companies are active in the sector although, to date, no single company has demonstrated proficiency across all four elements of the ADC supply chain: large molecule manufacture, drug conjugation, the toxic payload, and fill/ finish of the conjugate. Login \| Learn more...

Catching a Wave: How Much Will CMOs Benefit From Biosimilars?

Regulatory developments in the United States, coupled with impending patent expiry, have paved the way for the introduction of biosimilars of increasing technical complexity. In the European Union, 20 first wave biosimilars, consisting of growth hormones and relatively simple recombinant proteins, have already been approved. Of those first wave biosimilars, 30% have been outsourced to dose manufacturers, and 10% to API manufacturers. Login \| Learn more...

Opportunity Knocks: In-Licensed Drug Products Can Signal Outsourcing Opportunity

Of the more than 230 New Molecular Entities (NMEs) approved between 2003-2013, over one-third were in-licensed by the sponsor receiving the approval. A significant difference in manufacturing status emerged between products originally discovered in-house and those in-licensed from external partners. During this period 66% of in-licensed NMEs were either outsourced completely or partially, compared to 44% for internally discovered candidates. Login \| Learn more...

The Demand and Supply for Contract Manufacturing of Cytotoxic Injectable Drugs Through 2019

This report presents a detailed analysis of CMO industry capacity and the projected demand in the next five years and beyond. The research is based on an expert analysis of cytotoxic injectable drugs in the pipeline, including antibody drug conjugates (ADC)s. Login \| Learn more...

The Demand and Supply for Contract Manufacturing of Conventional Injectable Drugs Through 2019

This report provides an important expert quantitative analysis on the latest trends and plans for outsourcing commercially approved injectable products. The model and assumptions are fully explained so you can understand how the analysis was driven and how conclusions were reached. Login \| Learn more...

Archive

Contract Service Providers - Database

SEARCH by Service Provider

SEARCH by Announced Relationships

Emerging Markets Manufacturers - Database

Search by Service/Capability:

Product Search

Search known branded product approval data since 2005, including manufacturing sources. Earlier data provided if available.

Applicant Options

Applicant Name

Sponsor Type

Drug Characteristic Options

Proprietary Name

Generic Name

API Type

API Detail

API Process Technology

Dosage Form

Dosage Form Detail

Special Delivery Form

Packaging Detail

Route of Administration (ROA)

Approval Options

FDA Approval Type

FDA Approval Year

Start:

End:

Regulatory Pathway

Source/Manufacturing Options

API Manufacturing Source

API Manufacturer Name

Dose Manufacturing Source

Dose Manufacturer Name

Mergers and Acquisitions Search

Select the Buyer

Select the Target/Seller

Select the Transaction Nature

Select the Date Range

Start:

End:

Search by Ownership

Subject Search - Archives